Watson/Actavis: Name Is Just One Of Many Changes Resulting From Merger Completion
This article was originally published in The Pink Sheet Daily
Executive Summary
With the Actavis deal finalized, Watson achieves its long-sought goal of becoming a major international player in generics, and announces a new global management team to undertake the critical component: execution.
You may also be interested in...
Watson/Actavis Merger Requires Near Record Divestiture; Sandoz, Par Pick Up 18 Products
The required divestitures are quite significant relative to the size of the transaction: this is the second-largest divesture, but only the fifth-largest merger of generic firms.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.